Editas Medicine– tag –
-
First Report of CRISPR-Derived Base Editing in Human Embryos Achieves Precise DNA Changes While Avoiding Large Chromosomal Aberrations
CMN Weekly (CRISPR Medicine News) Unknown Overview CRISPR-derived base editing has been successfully applied to human embryos for the first time, achieving precise DNA changes while circumventing the large chromosomal aberrations typical... -
Intellia Therapeutics’ In Vivo CRISPR Therapy Lonvo-z Achieves 87% Attack Rate Reduction in HAE Phase 3 Trial, Initiates Rolling BLA Filing with FDA
Intellectia.AI USA Overview Intellia Therapeutics' in vivo CRISPR therapy, lonvo-z, demonstrated an 87% reduction in hereditary angioedema (HAE) attack frequency in its Phase 3 HAELO trial. Following these breakthrough results, the compa... -
Intellia Therapeutics Reports “Paradigm-Shifting” Phase 3 Data for Lonvoguran Ziclumeran, Achieving 87% Reduction in HAE Attacks with Single In Vivo CRISPR Dose
Fierce Biotech USA Overview Intellia Therapeutics announced groundbreaking Phase 3 HAELO trial data for lonvoguran ziclumeran (lonvo-z), an *in vivo* CRISPR gene-editing therapy for hereditary angioedema (HAE). This one-time treatment de... -
Beam Therapeutics Receives FDA IND Clearance for BEAM-304, Advancing Base Editing Therapy for Phenylketonuria (PKU) into Clinical Development
GlobeNewswire USA Overview Beam Therapeutics Inc. announced that the FDA has cleared its Investigational New Drug (IND) application for BEAM-304, a base editing therapy for Phenylketonuria (PKU). PKU is a rare genetic metabolic disorder ... -
Editas Medicine Unveils Positive Preclinical Data for Gene Editing Candidate EDIT-401, Demonstrating Significant Reduction in LDL, Lp(a), and ApoB in Non-Human Primates
Investing.com USA Overview Editas Medicine announced positive preclinical data for its gene editing therapeutic candidate EDIT-401, showing significant reductions in LDL cholesterol, lipoprotein(a) (Lp(a)), and apolipoprotein B (ApoB) in... -
REPROCELL Develops Hypoimmune iPSC Engineering with AI-Designed CRISPR for Off-the-Shelf Cell Therapies
REPROCELL Japan Overview REPROCELL announced a method to develop hypoimmune iPSCs using AI-designed CRISPR, leveraging its StemEdit gene-editing platform. This approach targets key immune recognition genes like B2M and CIITA to create un... -
Intellia Therapeutics’ Lonvo-z Anticipates Key Phase 3 HAE Data Presentation at EAACI 2026
Simply Wall St USA Overview Intellia Therapeutics highlighted that additional data from the Phase 3 HAELO trial of lonvo-z (lonvoguran ziclumeran), its CRISPR-based therapy for hereditary angioedema (HAE), will be presented at the Europe... -
CRISPR Therapeutics Demonstrates Future Potential with Casgevy Approval, Leading Gene-Editing Market Through Pipeline Diversification
Intellectia.AI USA Overview CRISPR Therapeutics has established market leadership with the FDA approval of Casgevy, its gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia. In 2025, 64 patients receive... -
CRISPR Therapeutics Honored with 2026 Global Recognition Award for Pioneering Gene-Editing Advances
Global Recognition Awards USA Overview CRISPR Therapeutics received the 2026 Global Recognition Award for its significant advancements in gene editing and personalized medicine. Leveraging CRISPR-Cas9 technology, the company has develope...
